These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

518 related items for PubMed ID: 30552940

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy.
    Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk AE, Grogan T, McCullough D, Bennett J, Bailey H, Lawrence HJ, Elashoff DA, Marks LS, Raman SS, Febbo PG, Reiter RE.
    J Urol; 2018 Sep; 200(3):564-572. PubMed ID: 29524506
    [Abstract] [Full Text] [Related]

  • 7. High prostate cancer gene 3 (PCA3) scores are associated with elevated Prostate Imaging Reporting and Data System (PI-RADS) grade and biopsy Gleason score, at magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy after a previous negative standard biopsy.
    De Luca S, Passera R, Cattaneo G, Manfredi M, Mele F, Fiori C, Bollito E, Cirillo S, Porpiglia F.
    BJU Int; 2016 Nov; 118(5):723-730. PubMed ID: 27112799
    [Abstract] [Full Text] [Related]

  • 8. Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate.
    Ullrich T, Quentin M, Arsov C, Schmaltz AK, Tschischka A, Laqua N, Hiester A, Blondin D, Rabenalt R, Albers P, Antoch G, Schimmöller L.
    J Urol; 2018 Mar; 199(3):691-698. PubMed ID: 28941924
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance.
    Radtke JP, Kuru TH, Boxler S, Alt CD, Popeneciu IV, Huettenbrink C, Klein T, Steinemann S, Bergstraesser C, Roethke M, Roth W, Schlemmer HP, Hohenfellner M, Hadaschik BA.
    J Urol; 2015 Jan; 193(1):87-94. PubMed ID: 25079939
    [Abstract] [Full Text] [Related]

  • 11. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I, Salmasi A, Mendhiratta N, Markovic D, Ahuja P, Hsu W, Elashoff DA, Raman SS, Reiter RE.
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
    Faiella E, Santucci D, Greco F, Frauenfelder G, Giacobbe V, Muto G, Zobel BB, Grasso RF.
    Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
    [Abstract] [Full Text] [Related]

  • 17. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    Luzzago S, de Cobelli O, Cozzi G, Peveri G, Bagnardi V, Catellani M, Di Trapani E, Mistretta FA, Pricolo P, Conti A, Alessi S, Marvaso G, Ferro M, Matei DV, Renne G, Jereczek-Fossa BA, Petralia G, Musi G.
    BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
    [Abstract] [Full Text] [Related]

  • 18. Percentage Gleason pattern 4 and PI-RADS score predict upgrading in biopsy Grade Group 2 prostate cancer patients without cribriform pattern.
    van der Slot MA, Seyrek N, Kweldam CF, den Bakker MA, Busstra MB, Gan M, Klaver S, Rietbergen JBW, van Leenders GJLH.
    World J Urol; 2022 Nov; 40(11):2723-2729. PubMed ID: 36190529
    [Abstract] [Full Text] [Related]

  • 19. Morphologic patterns observed in prostate biopsy cases with discrepant grade group and molecular risk classification.
    Greenland NY, Cooperberg MR, Carroll PR, Cowan JE, Simko JP, Stohr BA, Chan E.
    Prostate; 2024 Aug; 84(11):1076-1085. PubMed ID: 38734990
    [Abstract] [Full Text] [Related]

  • 20. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
    Patel HD, Koehne EL, Shea SM, Fang AM, Gorbonos A, Quek ML, Flanigan RC, Goldberg A, Rais-Bahrami S, Gupta GN.
    J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.